Zusammenfassung
Bis vor einigen Jahren existierte keine wirksame systemische Therapie für fortgeschrittene oder metastasierte gastrointestinale Stromatumoren (GIST). Der Tyrosinkinaseinhibitor Imatinib hat die Behandlung dieser Tumoren revolutioniert, die mediane Überlebenszeit liegt heute bei etwa 5 Jahren. Die Standarddosierung von Imatinib beträgt initial 400 mg/Tag. Lokal fortgeschrittene Tumoren werden primär systemisch behandelt und erst nach Ansprechen operiert. Imatinib wurde kürzlich auch für die adjuvante Behandlung von Patienten mit vollständig entferntem GIST und signifikantem Rezidivrisiko zugelassen.
Abstract
Until recently no active treatment for advanced or metastatic gastrointestinal stroma tumors (GIST) was available. The tyrosine kinase inhibitor imatinib has revolutionized the treatment of this disease and the median overall survival now reaches 5 years. The standard dose of imatinib is 400 mg per day. Locally advanced GIST should be treated with systemic therapy prior to surgical resection. Imatinib was recently licensed for adjuvant therapy following complete surgical removal of GIST in patients with a significant risk of recurrence.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480
Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625
Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatininb: randomized trial. Lancet 364:1127–1134
Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632
Van Glabbeke MM, Owzar K, Rankin C et al (2007) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1,640 patients. J Clin Oncol 25(18S):10004
Demetri GD, Wang Y, Wehrle E et al (2009) Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol May 18 [Epub ahead of print]
Casali PG, Jost L, Reichardt P et al (2009) Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:iv64–iv67
Blay JY, Le Cesne A, Ray-Coquard I et al (2007) Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumours comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25:1107–1113
Zalcberg JR, Verveij J, Casali PG et al (2005) Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751–1757
Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338
Blay JY, Casali PG, Reichardt P et al (2008) A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update. J Clin Oncol 26(20S):10553
Montemurro M, Schöffski P, Reichardt P et al (2008) Nilotinib in advanced GIST: a retrospective analysis of nilotinib in compassionate use. J Clin Oncol 26(15S):10523
Wiebe L, Kasza KE, Maki RG et al (2008) Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 26(20S):10502
Reichardt P, Montemurro M, Gelderblom H et al (2009) Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: a retrospective analysis. J Clin Oncol 27(15S):10564
DeMatteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104
Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465
Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23:70–83
Interessenkonflikt
Der Autor erhielt Berater- und Referentenhonorare von den Firmen Novartis und Pfizer sowie Studienunterstützung von der Firma Novartis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Reichardt, P. Internistische Therapie gastrointestinaler Stromatumoren. Radiologe 49, 1128–1131 (2009). https://doi.org/10.1007/s00117-009-1854-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-009-1854-7